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To the Editor: 
We read with interest the article by Weatherald et al. on the long-term outcomes of 
pulmonary arterial hypertension (PAH) induced by dasatinib [1]. The authors reported 
21 incident cases of PAH confirmed by right heart catheterisation (RHC) and 
associated with dasatinib. Although a majority of patients improved after dasatinib 
discontinuation, PAH persisted in over one-third of cases during long-term follow-up 
and two additional patients had persistent exercise pulmonary hypertension despite 
normalisation of resting haemodynamic measures. Similarly, Shah et al. reported 41 
cases of dasatinib-induced PAH confirmed by RHC with complete resolution of PAH 
in only 58% of patients, provided that follow-up RHC or echocardiography was most 
often not documented [2]. As mentioned by Weatherald and colleagues, these data 
suggest that dasatinib is likely to cause irreversible pulmonary vascular dysfunction 
and remodelling. An experimental model in rats and human pulmonary endothelial 
cells supports this hypothesis as it showed that dasatinib causes dose-dependent 
pulmonary endothelial dysfunction and apoptosis through the production of 
mitochondrial reactive oxygen species, a phenomenon that was not observed with 
imatinib [3]. To date, there is no published evidence of such pathological 
abnormalities on human lung. We report the case of a patient who developed 
dasatinib-induced severe PAH that progressed in spite of drug cessation and 
aggressive PAH-specific therapy and ultimately underwent lung transplantation. 
A 32-year old male was diagnosed with chronic myeloid leukaemia (CML) BCR-ABL1+ 
which was treated sequentially with imatinib, nilotinib and dasatinib. Thirty-six months 
after dasatinib initiation, he developed pre-capillary pulmonary hypertension confirmed 
by RHC with mean pulmonary arterial pressure (mPAP) of 57 mmHg, pulmonary 
artery wedge pressure (PAWP) of 9 mmHg, cardiac index of 1.4 L·min-1·m-2 and 
pulmonary vascular resistance (PVR) of 18.5 Wood units (WU), non-reactive to 
inhaled iloprost. Except for the above-mentioned tyrosine kinase inhibitors (TKIs), the 
patient had not been previously exposed to any chemotherapeutic agent or 
anorexigen drug. A comprehensive workup, including echocardiography, contrast-
enhanced computed tomography (CT) of the chest, ventilation/perfusion lung scan, 
abdominal ultrasound, autoimmunity screening and HIV serology, excluded other 
causes of pulmonary hypertension, which thus was attributed to dasatinib. At the time 
of PAH diagnosis, the patient presented with New York Heart Association (NYHA) 
functional class III and 6-min walk distance (6MWD) was 340m. Chest CT and 
echocardiography showed significant bilateral pleural effusions and a minor pericardial 
effusion. Following discontinuation of dasatinib and the introduction of PAH treatment 
combining a phosphodiesterase type 5 (PDE-5) inhibitor and an endothelin receptor 
antagonist (ERA), NYHA functional class improved to class I/II and 6MWD increased 
to 610m within 12 months. A follow-up RHC performed 10 months after PAH diagnosis 
confirmed significant haemodynamic improvement with mPAP decrease to 38 mmHg, 
cardiac index increase to 5.8 L·min-1·m-2 and near-normalisation of PVR to 2.8 WU. 
Owing to molecular relapse of CML, nilotinib was reintroduced at reduced dose (400 
mg·day-1) by considering that it was less likely than dasatinib to induce PAH. During 
the three years following nilotinib resumption and despite further dose reduction to 
200 mg·day-1, we observed a gradual clinical and functional worsening suggesting 
PAH progression. RHC was repeated and showed significant aggravation of PAH with 
an increase of mPAP to 70 mmHg, a drop of cardiac index to 2.2 L·min-1·m-2, a 
severe rise in PVR to 11.8 WU, as well as right atrial pressure above 14 mmHg and 
low mixed venous oxygen saturation as factors of poor prognosis. PAH therapy was 
intensified with continuous intravenous treprostinil infusion up to 40 ng·kg-1·min-1, in 
addition to maximal oral doses of PDE-5 inhibitor (sildenafil) and ERA (ambrisentan). 
However, PAH further progressed and over the following 6 months, the patient 
developed symptomatic right heart failure with NYHA functional class IV, exertional 
presyncopes, refractory hydrosodic retention and severe hypoxemia that ultimately 
necessitated continuous intravenous diuretics, recurrent thoracenteses, high flow 
oxygen therapy and haemodynamic support with noradrenaline and levosimendan 
infusions. In view of an immediately life-threatening situation due to PAH and given 
the favourable prognosis of CML on long-term TKI, it was decided, after 
multidisciplinary discussion, to perform bilateral lung transplantation which was 
successfully achieved under perioperative veno-arterial extracorporeal membrane 
oxygenation support, after 20 days on the waiting list. The patient was rapidly weaned 
off the hemodynamic support and extubated after three days. A transoesophageal 
echocardiography performed 24 hours after surgery showed normalisation of PAP 
and resolution of right ventricular dilatation with only minor residual dysfunction. After 
satisfactory cicatrisation of bronchial anastomoses and in the absence of imatinib 
resistance, imatinib 400 mg·day-1 was reintroduced. Six months after lung 
transplantation, CML is currently controlled on imatinib with undetectable BCR-ABL 
transcript level (major molecular response). No mutation in the BMPR2 gene was 
found.  
The analysis of the explanted lungs showed atherosclerosis and typical 
histopathological features of chronic PAH [4]. Pulmonary arteriopathy was 
characterised by major vascular wall remodelling with medial hypertrophy and 
concentric laminar intimal thickening, as well as plexiform lesions (Figure 1), without 
evidence of pulmonary veno-occlusive or thromboembolic disease. 
In our opinion, this case deserves attention as it suggests a possible severe evolution 
of dasatinib-induced PAH despite transition to nilotinib and maximal PAH-specific 
therapy. To our knowledge, there are no published data regarding lung transplantation 
in such a context. Moreover, this is the first case providing evidence of dasatinib-
induced characteristic pulmonary arterial remodelling in humans, as seen in other 
causes of PAH. It appears to confirm the hypothesis raised by Weatherald and 
colleagues of irreversible pulmonary vascular disease in patients with persistent PAH 
in spite of dasatinib discontinuation. It could also explain why, even though clinical and 
functional improvement is most often observed upon treatment discontinuation, 
abnormal haemodynamic can persist. In our case, it is interesting to note that PAH 
initially improved after dasatinib cessation and with dual PAH therapy, with near-
normalisation of PVR, and worsened only after nilotinib reintroduction, raising 
questions about the role of nilotinib in PAH progression. However, except for one case 
of suspected nilotinib-induced PAH without confirmation of diagnosis by RHC [5], there 
is currently no confirmed case of incident PAH caused by nilotinib, nor reported case 
of PAH worsening or relapse following replacement of dasatinib by nilotinib, although 
nilotinib is the most frequently used TKI after dasatinib withdrawal [6]. On the other 
hand, there have been published cases of incident or worsening PAH related to 
ponatinib or bosutinib in patients with previously documented dasatinib-induced pleural 
effusions or PAH [7-9]. Consequently, we cannot exclude that nilotinib, similarly to 
ponatinib and bosutinib, played some role in PAH progression and perpetuated 
pulmonary vascular toxicity following previous injury by dasatinib. Alternatively, the 
disease might have inevitably progressed, as seen in other forms of PAH, despite 
dasatinib withdrawal and after transient improvement on PAH therapy. 
The risk of PAH recurrence after lung transplantation and reintroduction of TKIs is 
unknown but seems unlikely as, on the one hand, it now depends on the 
predisposition of the pulmonary graft to PAH, and on the other hand, treatment with 
imatinib is not known to cause PAH and has even showed some beneficial effects in 
patients with PAH [10]. In case of resistance or intolerance to imatinib, rechallenge 
with dasatinib would be contraindicated. In the absence of previous graft exposure to 
dasatinib, the replacement of imatinib by nilotinib could be an option to be 
considered cautiously and with close monitoring.   
In conclusion, this extreme case illustrates the possible occurrence of irreversible 
pulmonary vascular remodelling and suggests that dasatinib induced PAH. It is 
difficult to implicate dasatinib conclusively as the sole agent responsible for the 
development of PAH in this case or in patients in the other reports. However, given 
the number of cases associated with dasatinib, it should be considered as a major 
factor in the development of PAH in CML patients.  
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Legend to figures: 
FIGURE 1 Histopathological features of dasatinib-induced pulmonary arteriopathy 
observed on explanted lungs: A) Small pulmonary artery with medial hypertrophy and 
concentric non-laminar intimal thickening, Hematoxylin Eosin (HE) stain, x100. B) 
Same lesion as A with van Gieson Elastin (VGE) stain for elastin highlighting the 
internal and external elastic laminae of the arterial wall, x100. C) Plexiform lesion 
corresponding to a complex vascular structure originating from remodelled pulmonary 
arteries and formed by focal proliferation of endothelial cells, HE stain, x200. D) Same 
lesion as C with VGE stain showing disruption of the elastic laminae associated with 
partial destruction and remodelling of the arterial walls, x200. E) Pulmonary arteriole 
beneath 70 µm showing complete obliteration through mainly intimal thickening, VGE 
stain, x400. Note: changes in small arterioles were heterogeneously distributed 
throughout the lung. F) Proximal pulmonary artery showing important atherosclerosis, 
HE stain, x40. Note: neither bronchial artery remodelling (hypertrophy/dilatation) nor 
pulmonary veins remodeling (smooth muscle hyperplasia and/or intimal fibrosis) were 
observed.  
 
 
 
